{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:11:47Z","timestamp":1794003107869,"version":"4.8.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.critrevonc.2024.104503","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T22:12:58Z","timestamp":1725660778000},"page":"104503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Minimal residual disease testing for classical Hodgkin lymphoma: A comprehensive review"],"prefix":"10.1016","volume":"204","author":[{"given":"Momo","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4711-7081","authenticated-orcid":false,"given":"Alaa","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Almasry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104503_bib1","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4","volume":"128","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2024.104503_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2024.104503_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib5","unstructured":"ANON 2024 The technology | clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia | Advice | NICE."},{"key":"10.1016\/j.critrevonc.2024.104503_bib6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ccell.2017.01.002","article-title":"Liquid Biopsies, What We Do Not Know (Yet)","volume":"31","author":"Bardelli","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2024.104503_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.seminhematol.2020.06.003","article-title":"Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement","volume":"57","author":"Bartram","year":"2020","journal-title":"Semin Hematol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"B\u00f6ttcher","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104503_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"B\u00f6ttcher","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104503_bib10","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104503_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/ph14030207","article-title":"Cell-free DNA for the management of classical hodgkin lymphoma","volume":"14","author":"Camus","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.critrevonc.2024.104503_bib12","first-page":"207","article-title":"Cell-free DNA for the management of classical hodgkin lymphoma","volume":"Vol. 14","author":"Camus","year":"2021","journal-title":"Pharmaceuticals 2021"},{"key":"10.1016\/j.critrevonc.2024.104503_bib13","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3109\/10428194.2016.1139703","article-title":"Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma","volume":"57","author":"Camus","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2024.104503_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104503_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104503_bib16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104503_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2015.134957","article-title":"Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study","volume":"101","author":"Cheminant","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104503_bib18","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2024.104503_bib19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.critrevonc.2024.104503_bib20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00277-009-0752-4","article-title":"Role of 18FDG-PET\/CT in detecting relapse during follow-up of patients with Hodgkin\u2019s lymphoma","volume":"88","author":"Crocchiolo","year":"2009","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib21","article-title":"Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia","volume":"43","author":"Dekker","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.critrevonc.2024.104503_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000749","article-title":"Blood-based Monitoring of Relapsed\/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment","volume":"6","author":"Drees","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.critrevonc.2024.104503_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jha2.826","article-title":"Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: Correlation with FDG-PET\/CT","volume":"5","author":"Fern\u00e1ndez","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.critrevonc.2024.104503_bib25","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib27","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00216-014-8405-4","article-title":"Isothermal circular-strand-displacement polymerization of DNA and microRNA in digital microfluidic devices","volume":"407","author":"Giuffrida","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.critrevonc.2024.104503_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.leukres.2017.09.018","article-title":"Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma","volume":"62","author":"Guidetti","year":"2017","journal-title":"Leuk. Res"},{"key":"10.1016\/j.critrevonc.2024.104503_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104503_bib30","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal Residual Disease Assessment in Lymphoma: Methods and Applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib31","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal Residual Disease Assessment in Lymphoma: Methods and Applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.critrevonc.2024.104503_bib34","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1182\/blood-2008-11-189688","article-title":"Circulating clonotypic B cells in classic Hodgkin lymphoma","volume":"113","author":"Jones","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib35","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"C.H.: Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12308-021-00470-8","article-title":"Serum thymus and activation-regulated chemokine (TARC) levels in newly diagnosed patients with Hodgkin lymphoma: a new promising and predictive tool? Preliminary report","volume":"14","author":"Kopi\u0144ska","year":"2021","journal-title":"J. Hematop"},{"key":"10.1016\/j.critrevonc.2024.104503_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031054","article-title":"Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia","volume":"21","author":"Kruse","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104503_bib38","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2024.104503_bib39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104503_bib40","first-page":"7209","article-title":"Principles of digital PCR and its applications in current obstetrical and gynecological diseases","volume":"11","author":"Mao","year":"2019","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.critrevonc.2024.104503_bib41","first-page":"7209","article-title":"Principles of digital PCR and its applications in current obstetrical and gynecological diseases","volume":"11","author":"Mao","year":"2019","journal-title":"Am. J. Transl. Res"},{"key":"10.1016\/j.critrevonc.2024.104503_bib42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V122.21.627.627","article-title":"Detection Of Classical Hodgkin Lymphoma In Peripheral Blood Using High-Throughput Sequencing Assay","volume":"122","author":"Oki","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib43","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13349","article-title":"Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach","volume":"169","author":"Oki","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib44","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13349","article-title":"Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach","volume":"169","author":"Oki","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3324\/haematol.2011.053199","article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Plattel","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104503_bib46","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V116.21.965.965","article-title":"R-CHOP\/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network","volume":"116","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib47","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.147.147","article-title":"MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network","volume":"124","author":"Pott","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.147.147","article-title":"MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network","volume":"124","author":"Pott","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib50","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib51","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib52","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7150\/jca.13593","article-title":"Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma","volume":"7","author":"Primerano","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104503_bib53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.20892\/j.issn.2095-3941.2018.0055","article-title":"Next-generation sequencing and its clinical application","volume":"16","author":"Qin","year":"2019","journal-title":"Cancer Biol. Med"},{"key":"10.1016\/j.critrevonc.2024.104503_bib54","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib55","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","author":"Roschewski","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104503_bib57","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104503_bib58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.12768","article-title":"Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma - results of the UK HD3 relapse treatment strategy","volume":"165","author":"Shankar","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib59","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib60","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104503_bib61","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.humpath.2008.06.032","article-title":"BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome","volume":"40","author":"Tibiletti","year":"2009","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2024.104503_bib62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.18473","article-title":"Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study","volume":"200","author":"Zijtregtop","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T04:03:10Z","timestamp":1732939390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824002464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":62,"alternative-id":["S1040842824002464"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104503","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal residual disease testing for classical Hodgkin lymphoma: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104503"}}